Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.76M | 1.30M | 69.96M | 86.95M | 64.87M |
Gross Profit | 1.25M | 380.00K | 68.57M | 68.11M | 48.90M |
EBITDA | -1.83M | -8.40M | 11.86M | -78.57M | -149.47M |
Net Income | -2.18M | -10.28M | 112.00M | -205.60M | -212.70M |
Balance Sheet | |||||
Total Assets | 38.82M | 43.31M | 90.46M | 169.47M | 181.61M |
Cash, Cash Equivalents and Short-Term Investments | 5.06M | 4.33M | 38.07M | 65.12M | 80.49M |
Total Debt | 7.17M | 8.01M | 8.76M | 196.33M | 246.37M |
Total Liabilities | 11.45M | 14.02M | 55.31M | 263.09M | 305.61M |
Stockholders Equity | 27.37M | 29.29M | 35.14M | -93.62M | -124.00M |
Cash Flow | |||||
Free Cash Flow | 1.17M | -48.14M | -4.43M | -144.92M | -161.07M |
Operating Cash Flow | 1.17M | -48.14M | -4.08M | -142.69M | -159.47M |
Investing Cash Flow | 0.00 | 0.00 | 223.48M | -2.22M | -1.60M |
Financing Cash Flow | 0.00 | 3.15M | -235.21M | 129.55M | 80.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $14.62M | ― | 3.29% | ― | -26.17% | ― | |
52 Neutral | $7.45B | -0.04 | -63.76% | 2.49% | 16.24% | <0.01% | |
49 Neutral | $8.94M | ― | -384.98% | ― | 14.27% | 87.31% | |
48 Neutral | $15.18M | ― | -58.71% | ― | -79.66% | -141.87% | |
47 Neutral | $13.31M | ― | -7.72% | ― | 35.25% | 81.05% | |
47 Neutral | $12.88M | ― | -58.30% | ― | ― | ― | |
31 Underperform | $37.04M | ― | -576.46% | ― | ― | 38.50% |
TherapeuticsMD reported a net loss from continuing operations of $2.3 million for the year ending December 31, 2024, a significant improvement from the previous year’s loss of $7.7 million. The company experienced a 35.3% increase in license revenue, primarily due to the Mayne License Agreement, and reduced its operating expenses by 33.6% as it continues to transition from a commercial business to a royalty-based model. TherapeuticsMD is also exploring strategic alternatives, including potential mergers or acquisitions, though no specific outcomes or timelines have been established.